Liaoning Chengda Biotechnology CO., LTD
7
1
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
57%
4 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
Role: lead
Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization
Role: lead
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
Role: lead
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
Role: lead
Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas
Role: lead
Phase I Clinical Trial of a Candidate PCV13 in Healthy People
Role: collaborator
Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province
Role: collaborator
All 7 trials loaded